BioRestorative Therapies, Inc. (BRTX)
- Previous Close
1.2700 - Open
1.2300 - Bid 1.2000 x 100
- Ask 1.2900 x 100
- Day's Range
1.2100 - 1.2800 - 52 Week Range
1.2000 - 7.1300 - Volume
61,454 - Avg. Volume
678,004 - Market Cap (intraday)
8.327M - Beta (5Y Monthly) 61.68
- PE Ratio (TTM)
-- - EPS (TTM)
-3.4200 - Earnings Date May 12, 2024 - May 16, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
10.50
BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.
www.biorestorative.comRecent News: BRTX
Performance Overview: BRTX
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BRTX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BRTX
Valuation Measures
Market Cap
8.33M
Enterprise Value
-2.56M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
35.59
Price/Book (mrq)
0.72
Enterprise Value/Revenue
-17.58
Enterprise Value/EBITDA
0.17
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-65.50%
Return on Equity (ttm)
-105.30%
Revenue (ttm)
145.8k
Net Income Avi to Common (ttm)
-14.42M
Diluted EPS (ttm)
-3.4200
Balance Sheet and Cash Flow
Total Cash (mrq)
11.07M
Total Debt/Equity (mrq)
1.41%
Levered Free Cash Flow (ttm)
-1.08M